Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Programmed Death ligand-1 (PD-L1) protein mediates immune suppression in cancer. Here, the authors show that in breast cancer, PD-L1 expression can be up regulated post-translationally by glycosylation, which in turn acts through inhibiting GSK3β-mediated PD-L1 degradation.
Main Authors: | Chia-Wei Li, Seung-Oe Lim, Weiya Xia, Heng-Huan Lee, Li-Chuan Chan, Chu-Wei Kuo, Kay-Hooi Khoo, Shih-Shin Chang, Jong-Ho Cha, Taewan Kim, Jennifer L. Hsu, Yun Wu, Jung-Mao Hsu, Hirohito Yamaguchi, Qingqing Ding, Yan Wang, Jun Yao, Cheng-Chung Lee, Hsing-Ju Wu, Aysegul A. Sahin, James P. Allison, Dihua Yu, Gabriel N. Hortobagyi, Mien-Chie Hung |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2016-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms12632 |
Similar Items
-
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
by: Ying-Nai Wang, et al.
Published: (2020-07-01) -
Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer
by: Hirohito eYamaguchi, et al.
Published: (2012-02-01) -
Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment
by: Zhou Jiang, et al.
Published: (2020-07-01) -
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
by: Jung-Mao Hsu, et al.
Published: (2018-05-01) -
Glycosylation of Immune Receptors in Cancer
by: Ruoxuan Sun, et al.
Published: (2021-05-01)